SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ascletis Files FDA IND for Oral Amylin Agonist ASC39

Ascletis submitted an FDA investigational new drug application for ASC39, an oral small-molecule selective amylin receptor agonist for obesity. The company expects to start a Phase I trial in Q4 2026.

1672

Related stories